The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database
Open accessAbstract
OBJECTIVE: To quantify the unintended effects of statins according to type, dose, and duration of use. DESIGN: Prospective open cohort study using routinely collected data. SETTING: 368 general practices in England and Wales supplying data to the QResearch database. PARTICIPANTS: 2 004 692 patients aged 30-84 years of whom 225 922 (10.7%) were new users of statins: 159 790 (70.7%) were prescribed simvastatin, 50 328 (22.3%) atorvastatin, 8103 (3.6%) pravastatin, 4497 (1.9%) rosuvastatin, and 3204 (1.4%) fluvastatin. METHODS: Cox proportional hazards models were used to estimate effects of statin type, dose, and duration of use. The number needed to treat (NNT) or number needed to harm (NNH) was calculated and numbers of additional or fewer cases estimated for 10 000 treated patients. MAIN OUTCOME MEASURE: First recorded occurrence of cardiovascular disease, moderate or serious myopathic events, moderate or serious liver dysfunction, acute renal failure, venous thromboembolism, Parkinson's disease, dementia, rheumatoid arthritis, cataract, osteoporotic fracture, gastric cancer, oesophageal cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer. RESULTS: Individual statins were not significantly associated with risk of Parkinson's disease, rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, gastric cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer. Statin use was associated with decreased risks of oesophageal cancer but increased risks of moderate or serious liver dysfunction, acute renal failure, moderate or serious myopathy, and cataract. Adverse effects were similar across statin types for each outcome except liver dysfunction where risks were highest for fluvastatin. A dose-response effect was apparent for acute renal failure and liver dysfunction. All increased risks persisted during treatment and were highest in the first year. After stopping treatment the risk of cataract returned to normal within a year in men and women. Risk of oesophageal cancer returned to normal within a year in women and within 1-3 years in men. Risk of acute renal failure returned to normal within 1-3 years in men and women, and liver dysfunction within 1-3 years in women and from three years in men. Based on the 20% threshold for cardiovascular risk, for women the NNT with any statin to prevent one case of cardiovascular disease over five years was 37 (95% confidence interval 27 to 64) and for oesophageal cancer was 1266 (850 to 3460) and for men the respective values were 33 (24 to 57) and 1082 (711 to 2807). In women the NNH for an additional case of acute renal failure over five years was 434 (284 to 783), of moderate or severe myopathy was 259 (186 to 375), of moderate or severe liver dysfunction was 136 (109 to 175), and of cataract was 33 (28 to 38). Overall, the NNHs and NNTs for men were similar to those for women, except for myopathy where the NNH was 91 (74 to 112). CONCLUSIONS: Claims of unintended benefits of statins, except for oesophageal cancer, remain unsubstantiated, although potential adverse effects at population level were confirmed and quantified. Further studies are needed to develop utilities to individualise the risks so that patients at highest risk of adverse events can be monitored closely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., Minhas, R., Sheikh, A., & Brindle, P. (2008) · BMJ · doi:10.1136/bmj.39609.449676.25 · Cited by 1,459
Self-citationCurrent Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,213
Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
The use of fractional polynomials to model continuous risk variables in epidemiology
Royston, P., Ambler, G., & Sauerbrei, W. (1999) · International Journal of Epidemiology · doi:10.1093/ije/28.5.964 · Cited by 1,066
Using the outcome for imputation of missing predictor values was preferred
Moons, K. G. M., Donders, R. A. R. T., Stijnen, T., & Harrell, F. E. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.009 · Cited by 994
Coronary heart disease statistics.
Allender, S. E., Peto, V., Scarborough, P., Kaur, A., & Rayner, M. (2008) · Deakin Research Online (Deakin University) · Cited by 928
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Tutorial in biostatistics: the self‐controlled case series method
Whitaker, H. J., Paddy Farrington, C., Spiessens, B., & Musonda, P. (2006) · Statistics in Medicine · doi:10.1002/sim.2302 · Cited by 719
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
HMG-CoA Reductase Inhibitors and the Risk of Fractures
Meier, C. R. (2000) · JAMA · doi:10.1001/jama.283.24.3205 · Cited by 445
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Thavendiranathan, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2307 · Cited by 351
Exposure to antipsychotics and risk of stroke: self controlled case series study
Douglas, I. J., & Smeeth, L. (2008) · BMJ · doi:10.1136/bmj.a1227 · Cited by 272
An Assessment of Statin Safety by Muscle Experts
Thompson, P. D., Clarkson, P. M., & Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.013 · Cited by 259
Alsheikh-Ali, A. A., Maddukuri, P. V., Han, H., & Karas, R. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.073 · Cited by 241
Case Series Analysis of Adverse Reactions to Vaccines: A Comparative Evaluation
Farrington, C. P., Nash, J., & Miller, E. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008695 · Cited by 235
Tolman, K. G. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02355-x · Cited by 214
Use of Statins and the Subsequent Development of Deep Vein Thrombosis
Ray, J. G., Mamdani, M., Tsuyuki, R. T., Anderson, D. R., Yeo, E. L., & Laupacis, A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1405 · Cited by 207
Bauer, D. C., Mundy, G. R., Jamal, S. A., Black, D. M., Cauley, J. A., Ensrud, K. E., van der Klift, M., & Pols, H. A. P. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.2.146 · Cited by 206
Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease
Huang, X., Chen, H., Miller, W. C., Mailman, R. B., Woodard, J. L., Chen, P. C., Xiang, D., Murrow, R. W., Wang, Y., & Poole, C. (2007) · Movement Disorders · doi:10.1002/mds.21290 · Cited by 189
Nichols, G. A., & Koro, C. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.022 · Cited by 173
Bonovas, S., Filioussi, K., Tsavaris, N., & Sitaras, N. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3560 · Cited by 172
LaCroix, A. Z., Cauley, J. A., Pettinger, M., Hsia, J., Bauer, D. C., McGowan, J., Chen, Z., Lewis, C. E., McNeeley, S. G., Passaro, M. D., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00009 · Cited by 169
Putting prevention first - vascular checks: risk assessment and management
Young, H. (2010) · Cited by 160
Continuation of Statin Treatment and All-Cause Mortality: A Population-Based Cohort Study
Shalev, V., Chodick, G., Silber, H., Kokia, E. S., Jan, J., & Heymann, A. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.552 · Cited by 154
Tannen, R. L., Weiner, M. G., & Xie, D. (2009) · BMJ · doi:10.1136/bmj.b81 · Cited by 152
Tata, L. J., West, J., Smith, C., Farrington, P., Card, T. R., Smeeth, L. L., & Hubbard, R. (2005) · Heart · doi:10.1136/hrt.2004.037457 · Cited by 143
Shepherd, J., Hunninghake, D. B., Stein, E. A., Kastelein, J. J. P., Harris, S., Pears, J. S., & Hutchinson, H. G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.049 · Cited by 140
Imputation is beneficial for handling missing data in predictive models
Steyerberg, E. W., & van Veen, M. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.003 · Cited by 110
Statin Use and Incident Nuclear Cataract
Klein, R., Klein, R., Lee, K. E., & Grady, L. M. (2006) · JAMA · doi:10.1001/jama.295.23.2752 · Cited by 110
Dangers of rosuvastatin identified before and after FDA approval
Wolfe, S. M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16513-6 · Cited by 74
Association of statin use with cognitive decline in elderly African Americans
Szwast, S. J., Hendrie, H. C., Lane, K. A., Gao, S., Taylor, S., Unverzagt, F. W., Murrell, J. R., Deeg, M. A., Ogunniyi, A. O., Farlow, M. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000279333.77404.d7 · Cited by 74
Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis
Jick, S. S., Choi, H. K., Li, L., McInnes, I. B., & Sattar, N. A. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091967 · Cited by 73
Long-Term Use of Statins and Risk of Colorectal Cancer: A Population-Based Study
Singh, H., Mahmud, S. M., Turner, D., Xue, L., Demers, A. A., & Bernstein, C. N. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.574 · Cited by 71
Hippisley‐Cox, J., & Coupland, C. A. C. (2010) · Heart · doi:10.1136/hrt.2010.199034 · Cited by 71
Self-citationGarcía‐Rodríguez, L. A., Massó-González, E. L., Wallander, M.-A. A., & Johansson, S. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1603 · Cited by 65
Do Statins Prevent Both Cardiovascular Disease and Fracture?
Cummings, S. R. (2000) · JAMA · doi:10.1001/jama.283.24.3255 · Cited by 65
Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials
Bonovas, S., Nikolopoulos, G. K., Filioussi, K., Peponi, E., Bagos, P. G., & Sitaras, N. M. (2009) · European Journal of Epidemiology · doi:10.1007/s10654-009-9396-x · Cited by 50
Cataract and the use of statins: a case-control study
Smeeth, L. L. (2003) · QJM · doi:10.1093/qjmed/hcg064 · Cited by 45
Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis
Andrade, S. E., Graham, D. J., Staffa, J. A., Schech, S. D., Shatin, D., Grenade, L. L., Goodman, M. J., Platt, R. G., Gurwitz, J. H., & Chan, K. A. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.004 · Cited by 44
Addeo, R., Altucci, L., Battista, T., Bonapace, I. M., Cancemi, M., Cicatiello, L., Germano, D., Pacilio, C., Salzano, S., Bresciani, F., et al. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0494 · Cited by 41
Linking environmental effects to health impacts: a computer modelling approach for air pollution
Mindell, J. S., & Barrowcliffe, R. (2005) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2005.036897 · Cited by 37
The self controlled case series method
Whitaker, H. (2008) · BMJ · doi:10.1136/bmj.a1069 · Cited by 34
Academic medicine: problems and solutions. The Academic Medicine Group.
(1989) · BMJ · doi:10.1136/bmj.298.6673.573 · Cited by 33
QRISK or Framingham for predicting cardiovascular risk?
Jackson, R., Marshall, R., Kerr, A., Riddell, T., & Wells, S. J. (2009) · BMJ · doi:10.1136/bmj.b2673 · Cited by 30
Academic medicine: problems and solutions
McAvoy, B. (1989) · BMJ · doi:10.1136/bmj.298.6676.830-d · Cited by 17
Cited by
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Metadata
- Authors
- Hippisley-Cox, J., & Coupland, C.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-05-20
- Volume
- 340
- Issue
- may19 4
- Pages
- c2197-c2197
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2157724767
- Cited by
- 512
- References
- 54
- FWCI
- 49.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.